PT Sarana Meditama Metropolitan Tbk (SAME.JK)
IDR 290.0
(-1.36%)
IDR 290.0
(-1.36%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 12.25 Billion IDR | 27.86% |
| 2022 | 9.58 Billion IDR | -93.35% |
| 2021 | 144.16 Billion IDR | 132.08% |
| 2020 | -449.46 Billion IDR | -292.94% |
| 2019 | -114.38 Billion IDR | -294.26% |
| 2018 | 58.88 Billion IDR | -18.23% |
| 2017 | 72.01 Billion IDR | 386.75% |
| 2016 | 14.79 Billion IDR | -73.86% |
| 2015 | 56.6 Billion IDR | -2.52% |
| 2014 | 58.06 Billion IDR | 24.48% |
| 2013 | 46.64 Billion IDR | 100.47% |
| 2012 | 23.26 Billion IDR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -6.45 Billion IDR | -551.14% |
| 2024 Q1 | 1.43 Billion IDR | -37.09% |
| 2024 Q3 | 1.6 Billion IDR | 124.85% |
| 2023 Q1 | 3.47 Billion IDR | -67.34% |
| 2023 Q4 | 2.27 Billion IDR | -80.16% |
| 2023 Q3 | 11.46 Billion IDR | 454.67% |
| 2023 Q2 | -3.23 Billion IDR | -193.12% |
| 2023 FY | 12.25 Billion IDR | 27.86% |
| 2022 Q3 | 18.48 Billion IDR | 158.17% |
| 2022 Q4 | 10.62 Billion IDR | -42.53% |
| 2022 FY | 9.58 Billion IDR | -93.35% |
| 2022 Q1 | 8.78 Billion IDR | 201.9% |
| 2022 Q2 | -31.78 Billion IDR | -461.82% |
| 2021 Q2 | 59.38 Billion IDR | 51.29% |
| 2021 Q3 | 48.53 Billion IDR | -18.28% |
| 2021 Q4 | -8.62 Billion IDR | -117.77% |
| 2021 FY | 144.16 Billion IDR | 132.08% |
| 2021 Q1 | 39.25 Billion IDR | 379.06% |
| 2020 FY | -449.46 Billion IDR | -292.94% |
| 2020 Q1 | -17.77 Billion IDR | 16.97% |
| 2020 Q2 | -29.67 Billion IDR | -66.95% |
| 2020 Q3 | -410.2 Billion IDR | -1282.36% |
| 2020 Q4 | 8.19 Billion IDR | 102.0% |
| 2019 Q1 | 4.16 Billion IDR | -50.76% |
| 2019 FY | -114.38 Billion IDR | -294.26% |
| 2019 Q4 | -21.4 Billion IDR | 78.11% |
| 2019 Q3 | -97.81 Billion IDR | -14625.77% |
| 2019 Q2 | 673.38 Million IDR | -83.83% |
| 2018 Q3 | 2.69 Billion IDR | -89.87% |
| 2018 FY | 58.88 Billion IDR | -18.23% |
| 2018 Q1 | 21.08 Billion IDR | 2260.07% |
| 2018 Q2 | 26.64 Billion IDR | 26.33% |
| 2018 Q4 | 8.45 Billion IDR | 213.39% |
| 2017 FY | 72.01 Billion IDR | 386.75% |
| 2017 Q1 | 22.61 Billion IDR | 201.41% |
| 2017 Q2 | 23.95 Billion IDR | 5.89% |
| 2017 Q3 | 24.54 Billion IDR | 2.49% |
| 2017 Q4 | 893.55 Million IDR | -96.36% |
| 2016 Q1 | 24.85 Billion IDR | 21.13% |
| 2016 FY | 14.79 Billion IDR | -73.86% |
| 2016 Q4 | 7.5 Billion IDR | -7.28% |
| 2016 Q3 | 8.09 Billion IDR | 131.54% |
| 2016 Q2 | -25.66 Billion IDR | -203.23% |
| 2015 Q2 | 17.34 Billion IDR | 25.53% |
| 2015 Q1 | 13.81 Billion IDR | -14.55% |
| 2015 FY | 56.6 Billion IDR | -2.52% |
| 2015 Q4 | 20.52 Billion IDR | 316.72% |
| 2015 Q3 | 4.92 Billion IDR | -71.61% |
| 2014 Q2 | 14.39 Billion IDR | 23.3% |
| 2014 FY | 58.06 Billion IDR | 24.48% |
| 2014 Q4 | 16.16 Billion IDR | 2.17% |
| 2014 Q1 | 11.67 Billion IDR | -27.32% |
| 2014 Q3 | 15.82 Billion IDR | 9.91% |
| 2013 Q1 | 7.31 Billion IDR | 28.47% |
| 2013 Q3 | 12.15 Billion IDR | 9.48% |
| 2013 Q4 | 16.06 Billion IDR | 32.13% |
| 2013 FY | 46.64 Billion IDR | 100.47% |
| 2013 Q2 | 11.1 Billion IDR | 51.83% |
| 2012 FY | 23.26 Billion IDR | 0.0% |
| 2012 Q4 | 5.69 Billion IDR | 18.46% |
| 2012 Q3 | 4.8 Billion IDR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| PT Bundamedik Tbk | 7.46 Billion IDR | -64.214% |
| PT Metro Healthcare Indonesia Tbk | -110.91 Billion IDR | 111.046% |
| PT Medikaloka Hermina Tbk | 437.34 Billion IDR | 97.199% |
| PT Mitra Keluarga Karyasehat Tbk | 916.13 Billion IDR | 98.663% |
| PT Murni Sadar Tbk | -12.83 Billion IDR | 195.483% |
| PT Famon Awal Bros Sedaya Tbk | 216.97 Billion IDR | 94.353% |
| PT Royal Prima Tbk | -2.74 Billion IDR | 546.102% |
| PT Kedoya Adyaraya Tbk | 25.18 Billion IDR | 51.359% |
| PT Siloam International Hospitals Tbk | 1211.28 Billion IDR | 98.988% |
| PT Sejahteraraya Anugrahjaya Tbk | -38.49 Billion IDR | 131.832% |